App-Quantinova.ai

Intervention programs to improve oral chemotherapy safety and quality.

Benjamin Adam Goldenberg - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

The Geriatric-Oncologic Conference: A new approach in decision-making.

Sebastian Willy Ertl - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Trend in treatment aggressiveness at the end of life in an Italian homogeneous area: Preliminary data.

Davide Tassinari - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Collection of adverse events data for the supplemental indications in cancer clinical trials: Is it needed?

Sirisha Mushti - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Facilitating the delivery of patient-centered cancer care: Insights from the Patient-Centered Outcomes Research Institutes (PCORI) cancer portfolio.

Neeraj K. Arora - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Pharmacoeconomic analysis of dalteparin vs. vitamin k antagonists (VKA) for the prevention of recurrent venous thromboembolism (VTE) in cancer patients with renal insufficiency.

George Dranitsaris - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

dalteparin Subcutaneous

The impact of cancer treatment on work productivity of patients and caregivers: A systematic review of the evidence.

Jordan Randall Covvey - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Reliability and consistency of three value frameworks for oncology therapeutics.

Tanya G.K. Bentley - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Impact of variable fee schedule reimbursement (VFSR) on anti-emetic utilization and quality of care.

Maria Lopes - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Palonosetron

Systematic review of overuse in oncology.

Shrujal S. Baxi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Three years of reimbursement decisions regarding novel oncology drugs in Israel: A retrospective evaluation of correspondence with the ESMO Magnitude of Clinical Benefit Scale.

Ariel Hammerman - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Predictors of financial burden at a comprehensive cancer center.

Sheetal Mehta Kircher - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Cancer patient experience with financial counseling among participants of an online registry.

Joanne S. Buzaglo - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Development and use of a staffing model for clinical research teams at an NCI Comprehensive Cancer Center.

Erin Fenske Williams - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Financial distress among older versus younger adults with cancer.

Thomas Gregory Knight - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

The role of patient financial assistance programs (PAPs) in reducing costs for cancer patients.

Yousuf Zafar - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Pilot study of an online app to reduce cancer patients financial burden.

Yousuf Zafar - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Cost-effectiveness analysis of elective neck dissection in patients with clinically node negative oral cavity cancer.

Joseph Roy Acevedo - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Evaluation of value in non-inferiority trials by ASCOs conceptual framework.

Kenichi Miyamoto - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Quality and cost comparison of powered versus manual bone marrow biopsy devices at a large U.S. cancer center.

Abhishek Maiti - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Filters

41730 Abstracts